Related Experiment Video

Updated: Aug 21, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Erectile dysfunction in heart disease patients

I Sainz1, J Amaya, M Garcia

  • 1Cardiology Department, Cardiac Rehabilitation Center, Hospital de Valme, Seville, Spain. ignacio.sainz.sspa@juntadeandalucia.es

International Journal of Impotence Research
|October 22, 2004
PubMed

Insights

Erectile dysfunction (ED) is common in heart disease patients due to atherosclerosis and medications. Sexual activity is generally safe for patients who can complete two stages of the Bruce protocol, with sildenafil often a suitable treatment.

Area of Science:

  • Cardiology
  • Urology
  • Sexual Medicine

Background:

  • Atherosclerosis affects both coronary and penile arteries, contributing to erectile dysfunction (ED) in heart disease patients.
  • ED in these patients is multifactorial, involving organic, psychological, and pharmacological causes, including medications for cardiovascular conditions.
  • The incidence of ED post-myocardial infarction is significant, ranging from 38% to 78%.

Purpose of the Study:

  • To assess the cardiovascular risk associated with sexual activity in heart disease patients.
  • To establish guidelines for managing erectile dysfunction in patients with cardiovascular disease.
  • To determine appropriate treatment strategies for ED in this population.

Main Methods:

  • Evaluation of cardiovascular risk through medical history, echocardiography, and stress testing (Bruce protocol).
  • Assessment of energy expenditure during sexual intercourse (3.7-5 METs).
  • Review of contraindications and recommendations for oral ED treatments.

Main Results:

  • Sexual intercourse requires moderate energy expenditure (up to 5 METs), generally considered safe for patients with a functional capacity exceeding 7 METs (achieved by completing two stages of the Bruce protocol).
  • Sildenafil is recommended as a first-line oral therapy for ED in heart disease patients when sexual activity is not contraindicated.
  • Specific contraindications and treatment recommendations are discussed.

Conclusions:

  • Sexual activity can be safely undertaken by many heart disease patients with ED, provided cardiovascular risk is assessed.
  • Oral sildenafil is a viable and effective treatment option for ED in stable heart disease patients.
  • A comprehensive approach integrating cardiovascular assessment and appropriate ED pharmacotherapy is crucial.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...